Clinical trials: Emerging Infectious Diseases, open to volunteers
Infectious Diseases in Febrile Patients Returning From Tropical Countries
Rapid Molecular Diagnosis and Detection of Emerging Infectious Diseases in Patients With Tropical Fever (Tropifever)
Travellers returning from tropical countries often present to emergency departments with acute fever. While systematic screening for malaria is well established in clinical practice in France, further diagnostic testing for…
- Trial name
- Tropifever (NCT06539325)
- Testing
- Diagnosis algorithm according to the delay between travel and consultation
- Where
- France
- Volunteers
- 564 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Urinary Tract Infections, Antiobiotic Stewardship
Post-Emergency Optimization of Antibiotic Therapy for Urinary Tract Infection (UTI)
Prospective, multicenter, non-interventional study conducted over 6 months, including patients presenting to the emergency department with suspected urinary tract infection managed as outpatients and discharged with or without…
- Conditions
- Urinary Tract Infections, Antiobiotic Stewardship, Emerging Infectious Disease
- Trial name
- REVIU48 (NCT07559318)
- Testing
- Adaptation of antibiotics therapy for outpatient urinary infection following emergency care
- Where
- 3 sites in France
- Volunteers
- 330 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Emerging Infectious Diseases, Communicable Diseases
Establishment of a Biobank for the Evaluation of Rapid Diagnostic Solutions
This multicenter prospective registry aims to establish a biobank of residual biological samples and associated clinical data from hospitalized patients.
- Conditions
- Emerging Infectious Diseases, Communicable Diseases, Biological Warfare Agents, Zoonoses
- Trial name
- NCT07411729
- Where
- 10 sites in France
- Volunteers
- 800 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
HIV - Human Immunodeficiency Virus, HIV Antiretroviral Therapy (ART) Adherence
Improving the HIV Care Continuum With mHealth Technology
Youth living with HIV (YLHIV) face barriers to engagement and retention in HIV care, show poor medication adherence, and often fail to achieve and maintain viral suppression.
- Conditions
- HIV - Human Immunodeficiency Virus, HIV Antiretroviral Therapy (ART) Adherence, mHealth Application, mHealth Intervention
- Trial name
- NCT07631104
- Testing
- MindBodyU Intervention
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of South Carolina
Leishmaniasis, Leptospirosis
Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases
Zoonoses and arboviroses refer to a group of diseases transmitted from animals to humans, either directly or indirectly (via mosquitoes, ticks or contact with contaminated environments).
- Conditions
- Leishmaniasis, Leptospirosis, Brucellosis, Q Fever
- Trial name
- SEZAM (NCT06859619)
- Testing
- Peripheral venous blood sample
- Where
- France
- Volunteers
- 183 people
- Sponsor
- University Hospital, Montpellier
COVID-19 Infection
Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). The global outbreak of COVID-19 is a major public health problem. COVID-19 causes a wide range of symptoms.
- Trial name
- NCT04582903
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Mild Leptospirosis
Comparing Two Antibiotic Therapy Periods (3 Versus 7 Days) in Patients With Mild Leptospirosis and Seen at the Hospital in 5 French Overseas Departments (Martinique, Guadeloupe, French Guiana, Reunion, Mayotte)
Leptospirosis is a globally distributed neglected tropical disease affecting subtropical and tropical areas, such as the Caribbean and the Indian Ocean, with favorable climatic conditions for disease transmission.
- Trial name
- LEPTO3 (NCT04211649)
- Testing
- 3 days of antibiotherapy
- Where
- 5 sites in French Guiana, Guadeloupe and 3 more
- Volunteers
- 220 people
- Sponsor
- University Hospital Center of Martinique
Infectious Diseases and Manifestations
Cohort of the Specialist Network Infectious Diseases
This observational study aims to collect standardized clinical data and biosamples from adults in university hospitals across Germany.
- Trial name
- SNID (NCT06879184)
- Where
- Germany
- Volunteers
- 15,000 people
- Sponsor
- Goethe University
Urinary Tract Infection
Microbiological Characterization and Antibiotic Resistance Profiling of Providencia Spp,: An Emerging Pathogen Isolated From Urinary Tract Infections
Aims of the Research: 1. Isolation and identification of Providencia spp. from UTIs. 2. Genotypic confirmation of Providencia isolates. 3. Determination of antimicrobial sensitivity patterns of isolated Providencia spp. 4.
- Trial name
- NCT07204769
- Testing
- Antibiotic sensitivity
- Where
- Egypt
- Volunteers
- 241 people
- Sponsor
- Assiut University
Emerging Infectious Diseases and Their Treatments
Biological Collection on Emerging Infectious Diseases and Their Treatments
Unprecedented changes in human-environment interactions and increasing disruptions to ecosystems and the climate have contributed to the emergence of infectious diseases (Emerging Infectious Diseases, EIDs).
- Trial name
- COMETE (NCT07674550)
- Where
- France
- Volunteers
- 5,300 people
- Sponsor
- University Hospital, Toulouse
Invasive Fungal Disease
FungiScope - A Global Emerging Fungal Infection Registry
The objective of this registry is to broaden the knowledge on epidemiology, diagnostic procedures and clinical course of emerging invasive fungal infections.
- Trial name
- FungiScope (NCT01731353)
- Where
- Germany
- Volunteers
- 1,000 people
- Sponsor
- University of Cologne
Post-COVID-19 Condition, Ulcerative Colitis
Emerging Indications for Hyperbaric Oxygen Treatment
This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric…
- Conditions
- Post-COVID-19 Condition, Ulcerative Colitis, Crohn Disease, Calciphylaxis
- Trial name
- NCT07240649
- Testing
- Hyperbaric oxygen treatment (HBOT), 100% Oxygen
- Volunteers
- 100 people
- Sponsor
- Jay C. Buckey Jr.
Rift Valley Fever, Hemorrhagic Fevers, Viral
RVF and Other Emerging Infectious Diseases in East and Central Africa
Rift Valley fever (RVF), a disease transmitted from livestock (cattle, sheep, goats, camels) to humans more commonly occurs in the East and Central Africa (ECA) regions where more than 15 major epidemics affecting more than one…
- Trial name
- NCT05139524
- Testing
- Evidence of past or recent RVF exposure
- Where
- 10 sites in Democratic Republic of the Congo, Kenya and 2 more
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Washington State University
Lassa Fever
ISTH/ANRS 0409s INTEGRATE Lassa Fever Study
Lassa fever (LF) is a viral haemorrhagic fever responsible of 5000 deaths per year in West Africa, with in-hospital mortality at 12%.
- Trial name
- NCT06212336
- Testing
- Favipiravir, Ribavirin, Dexamethasone
- Where
- 4 sites in Liberia, Nigeria
- Volunteers
- 1,755 people
- Sponsor
- Irrua Specialist Teaching Hospital
Emerging Infectious Diseases, COVID-19
Smart Analysis and Decision-Making for Emerging Infectious Diseases
Emerging infectious diseases, such as COVID-19, mpox, and dengue fever, are characterized by rapid transmission, wide impact, and high uncertainty, posing ongoing threats to global public health.
- Conditions
- Emerging Infectious Diseases, COVID-19, Influenza, Mpox (Monkeypox)
- Trial name
- SMART-ID (NCT07678619)
- Testing
- Multi-Agent Integrated Smart Toolkit for Emerging Infectious Diseases, Routine Practices
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Peking University
Arbovirus Infections, Respiratory Infection Virus
Cohort Study of Arbovirus and Other Emerging Virus Infections in Fiji: AEVI-Fiji Cohort.
Background: Fiji, an archipelago in the South Pacific comprising 332 islands distributed among 4 health administrative divisions (Central, Western, Eastern, Northern), is particularly vulnerable to the (re-)emergence of…
- Trial name
- AEVI-Fiji (NCT07229677)
- Where
- Fiji
- Volunteers
- 910 people, healthy volunteers welcome
- Sponsor
- Fiji National University
Mpox (Monkeypox), Monkeypox Virus Infection
DiagRaMIE Mpox Virus-RDC for the Diagnostic of Monkeypox
Monkeypox, caused by a virus in the Orthopoxvirus genus, is a zoonotic disease first identified in 1970 in the Democratic Republic of Congo (DRC).
- Trial name
- DiagRaMIE Mpox (NCT06840197)
- Testing
- NG-TestⓇ Monkeypox virus kit
- Where
- 3 sites in Republic of the Congo
- Volunteers
- 197 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Primary or Secondary Immune Deficiency Including Immunosuppressive Therapy, Chemotherapy, HIV Infection
Performance of Clinical Metagenomics in Stool and Urine Samples for Unexplained Diseases Diagnostic and Emerging Diseases Surveillance in Immunocompromised Patients
The study is based on the hypothesis that the concomitant use of mNGS in non-invasive samples (stool, urine) could improve the rate of detected pathogens in immunodeficient patients compared with mNGS performed in an invasive…
- Trial name
- SENTINEL (NCT07603453)
- Testing
- Metagenomics
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Ebola, Bundibugyo Virus Disease (BVD)
BRAVO is a Phased Outbreak-response Study in the DRC Evaluating ERVEBO® Vaccination in ~20,000 Frontline Workers During the 2026 BDV Outbreak, Step A Assesses Real-world Effectiveness, Safety, and Impact on Severe Disease and Mortality, While Generating Evidence for Future BDV Vaccination Strategies
The BRAVO study (Bundibugyo: Respondre Avec la Vaccination, "On est ensemble") was developed in response to the 2026 Bundibugyo virus disease (BVD) outbreak in the Democratic Republic of the Congo (DRC).
- Trial name
- BRAVO (NCT07903350)
- Testing
- ERVEBO Vaccination
- Where
- Democratic Republic of the Congo
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Epicentre
Occupational Accidents, Incubation Period, Infectious Disese
Admission and Management of Occupational or Other Exposures to Biodefense/Bioterrorism Agents or to Epidemic/Emerging Infectious Diseases
Background: Increased clinical attention has been paid to the evaluation and management of bioterrorism-related illness (such as anthrax infection) and emerging infectious diseases (such as Severe Acute Respiratory Syndrome…
- Trial name
- NCT01200953
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)